Afamelanotide (Scenesse, Melanotan-I)
FDA-approved synthetic α-MSH analog used in erythropoietic protoporphyria — the regulated, clinically validated cousin of Melanotan II.
At a glance
What it is: FDA-approved synthetic α-MSH analog used in erythropoietic protoporphyria — the regulated, clinically validated cousin of Melanotan II..
Primary research applications:
- Erythropoietic protoporphyria (EPP) — phototoxicity prevention
Editorial summary: Afamelanotide (Scenesse) is the FDA-approved member of the melanocortin family — a slow-release subcutaneous implant used in erythropoietic protoporphyria. It demonstrates that the melanocortin pathway can be engineered into a focused, regulated therapeutic; its existence is also useful context for understanding the structurally similar but unregulated Melanotan II.
- Class / structure
- 13-amino-acid α-MSH analog (Nle⁴, D-Phe⁷ substitutions)
- Half-life
- Sustained release from subcutaneous implant over ~2 months
- First described
- 1980s (University of Arizona)
- Regulatory status
- FDA-approved (Scenesse 2019); EMA-approved 2014
What is Afamelanotide?
Afamelanotide is a 13-amino-acid synthetic analog of α-melanocyte-stimulating hormone (α-MSH), selectively engineered for stability and MC1R agonist activity.
Discovery and development
Afamelanotide was discovered at the University of Arizona by Hadley, Hruby and colleagues in the 1980s — the same melanocortin research program that produced Melanotan II. It was developed by Clinuvel Pharmaceuticals as a slow-release subcutaneous implant for erythropoietic protoporphyria (EPP), a rare hereditary photosensitivity disorder. EMA approval came in 2014; FDA approval followed in 2019.
Mechanism of action
MC1R activation on melanocytes promotes eumelanin production, which absorbs UV and visible light. In EPP — where photosensitivity is driven by accumulation of protoporphyrin IX in skin and reaction with visible light — increased eumelanin reduces dermal phototoxicity.[1]
Pharmacokinetics
Afamelanotide is delivered as a 16 mg slow-release implant placed subcutaneously every two months. The implant releases drug over approximately two months, achieving sustained MC1R activation and increased eumelanin production.
What the research shows
The peer-reviewed literature on Afamelanotide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Increases pain-free sun exposure in EPP | CLEAR trial | Supported |
| Is safer than research-grade Melanotan II | Different molecule, regulated formulation, monitored implant delivery | Supported |
| Should be used as a tanning agent | EPP-only labeling; cosmetic tanning use is off-label and not the intended indication | Unsupported |
Reported user experiences
How the research describes administration
Subcutaneous implant placed by a clinician every two months, in EPP-treatment specialty centers.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Afamelanotide is the FDA-approved member of the melanocortin therapeutic family — and a useful contrast point with Melanotan II. Same general molecular family, very different regulatory and clinical realities. Its existence shows what clinical melanocortin therapy looks like when developed under modern drug-development standards.
Frequently asked questions
Is afamelanotide the same as Melanotan I?
Yes — they are the same molecule. Melanotan I was the research designation; afamelanotide (Scenesse) is the approved drug name.
Is Scenesse used for cosmetic tanning?
It is FDA-approved specifically for EPP. Cosmetic tanning use is off-label and not the basis of its regulatory approval.
References
- Minder EI, Schneider-Yin X. Afamelanotide for the treatment of erythropoietic protoporphyria. Clin Drug Investig. 2017;37(11):1015-1024. https://pubmed.ncbi.nlm.nih.gov/28752370/
- Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. https://pubmed.ncbi.nlm.nih.gov/26132941/